Ad Scientiam and Abata Therapeutics are working together on digital biomarkers.

Ad Scientiam has partnered with Abata Therapeutics to provide digital biomarker expertise for a Phase I clinical research of ABA-101, a potential treatment for progressive multiple sclerosis (MS). Ad Scientiam will use its MSCopilot® technology to monitor and describe functional metrics in trial participants, assisting in the evaluation of illness progression and treatment efficacy.

This partnership is a big step forward for Ad Scientiam’s position in clinical research, as the business will apply its innovative digital biomarker technology to Abata Therapeutics’ first-in-human trial of ABA-101. Ad Scientiam’s MSCopilot® software will be tailored to the study’s needs, tracking important parameters impacted by MS such as mobility, upper extremity function, cognition, and vision.

Dr. Saad Zinaï, Ad Scientiam’s Chief Medical Officer, expressed enthusiasm about the collaboration, highlighting the potential of their technology to detect subtle disease changes and validate new therapies. Leonard L. Dragone, M.D., Ph.D., Chief Medical Officer at Abata, noted the importance of integrating digital biomarkers to better understand and measure disability in MS patients during the trial.

The partnership leverages Ad Scientiam’s expertise in digital health tools, enhancing Abata Therapeutics’ ability to obtain high-frequency disability measures throughout the trial. Financial details of the collaboration were not disclosed, but the synergy between the two companies aims to advance treatment options for progressive MS, a condition currently lacking sufficient therapeutic solutions.